Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Nature
Robichaux, Jacqulyne P JP; Le, Xiuning X; Vijayan, R S K RSK; Hicks, J Kevin JK; Heeke, Simon S; Elamin, Yasir Y YY; Lin, Heather Y HY; Udagawa, Hibiki H; Skoulidis, Ferdinandos F; Tran, Hai H; Varghese, Susan S; He, Junqin J; Zhang, Fahao F; Nilsson, Monique B MB; Hu, Lemei L; Poteete, Alissa A; Rinsurongkawong, Waree W; Zhang, Xiaoshan X; Ren, Chenghui C; Liu, Xiaoke X; Hong, Lingzhi L; Zhang, Jianjun J; Diao, Lixia L; Madison, Russell R; Schrock, Alexa B AB; Saam, Jennifer J; Raymond, Victoria V; Fang, Bingliang B; Wang, Jing J; Ha, Min Jin MJ; Cross, Jason B JB; Gray, Jhanelle E JE; Heymach, John V JV
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
International Journal Of Molecular Sciences
Russo, Alessandro A; Franchina, Tindara T; Ricciardi, Giuseppina G; Battaglia, Alessandra A; Picciotto, Maria M; Adamo, Vincenzo V
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
Chinese Journal Of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology
Kopetz, Scott S; Desai, Jayesh J; Chan, Emily E; Hecht, Joel Randolph JR; O'Dwyer, Peter J PJ; Maru, Dipen D; Morris, Van V; Janku, Filip F; Dasari, Arvind A; Chung, Woonbook W; Issa, Jean-Pierre J JP; Gibbs, Peter P; James, Brian B; Powis, Garth G; Nolop, Keith B KB; Bhattacharya, Suman S; Saltz, Leonard L
EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.